Cyclin dependent kinase 2 (CDK2) is a well-known regulator of the cell cycle in diverse types of cells. In pancreatic β-cells, CDKs have been the subject of much research devoted towards increasing β-cell mass by driving proliferation in diabetics, where there is a conspicuous loss of β-cell mass. However, mice lacking CDK2 in their pancreatic β-cells (Pdx1-Cre:CDK2–/– mice) exhibited glucose intolerance and reduced insulin release from isolated islets before losing β-cell mass. To examine the underlying defects, optical imaging of NAD(P)H/flavin autofluorescence was used to directly measure glycolytic and mitochondrial activity, which both trigger and control refilling of the readily-releasable granule pool in β-cells. By comparison to control islets, Pdx1-Cre:Cdk2–/– islets exhibited a reduced baseline, slower rise time, and a reduced maximal NAD(P)H/flavin response, which correlated with increased mitochondrial volume in EM images. Surprisingly, Ca2+ signaling - the direct trigger for β-cell insulin granule release - was not responsible for the observed secretory defect since the intracellular Ca2+ oscillations of Pdx1-Cre:Cdk2–/– islets were found to be more sensitive to glucose than control islets. Ca2+ channel activation is therefore uncoupled from both metabolism and secretion in this model. Uncoupling of secretion may further involve the exocytotic machinery, since mRNA levels of the SNARE protein SNAP25, and the glucose-dependent priming factor RAB27A, were reduced by CDK2 ablation. Taken together, our data indicates that CDK2 maintains insulin secretion by regulating metabolic output and plasma membrane electrical activity, and suggests further CDK2-dependent regulation of the exocytotic machinery, roles that are in distinct to regulation of β-cell proliferative capacity. Supported by F32DK085960 (MJM), the NIDDK Intramural Research Program (SGR), and R01DK46409 (LSS).
Read full abstract